510 related articles for article (PubMed ID: 19004988)
21. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Canalli AA; Franco-Penteado CF; Saad ST; Conran N; Costa FF
Haematologica; 2008 Apr; 93(4):605-9. PubMed ID: 18326523
[TBL] [Abstract][Full Text] [Related]
22. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
23. Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises.
Barbu EA; Mendelsohn L; Samsel L; Thein SL
Cytokine; 2020 Mar; 127():154933. PubMed ID: 31778959
[TBL] [Abstract][Full Text] [Related]
24. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.
da Silva Rocha LB; Dias Elias DB; Barbosa MC; Bandeira IC; Gonçalves RP
Mutat Res; 2012 Dec; 749(1-2):48-52. PubMed ID: 22918118
[TBL] [Abstract][Full Text] [Related]
25. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
Odièvre MH; Bony V; Benkerrou M; Lapouméroulie C; Alberti C; Ducrocq R; Jacqz-Aigrain E; Elion J; Cartron JP
Haematologica; 2008 Apr; 93(4):502-10. PubMed ID: 18322255
[TBL] [Abstract][Full Text] [Related]
26. Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia.
Athanassiou G; Moutzouri A; Kourakli A; Zoumbos N
Clin Hemorheol Microcirc; 2006; 35(1-2):291-5. PubMed ID: 16899945
[TBL] [Abstract][Full Text] [Related]
27. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
Lanzkron S; Haywood C; Segal JB; Dover GJ
Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
[TBL] [Abstract][Full Text] [Related]
28. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
Cartron JP; Elion J
Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
[TBL] [Abstract][Full Text] [Related]
29. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of NADPH oxidase components and increased production of interferon-gamma by leukocytes from sickle cell disease patients.
Marçal LE; Dias-da-Motta PM; Rehder J; Mamoni RL; Blotta MH; Whitney CB; Newburger PE; Costa FF; Saad ST; Condino-Neto A
Am J Hematol; 2008 Jan; 83(1):41-5. PubMed ID: 17654682
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
32. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
33. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Lapouméroulie C; Benkerrou M; Odièvre MH; Ducrocq R; Brun M; Elion J
Haematologica; 2005 Mar; 90(3):401-3. PubMed ID: 15749673
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients.
Guarda CC; Silveira-Mattos PSM; Yahouédéhou SCMA; Santiago RP; Aleluia MM; Figueiredo CVB; Fiuza LM; Carvalho SP; Oliveira RM; Nascimento VML; Luz NF; Borges VM; Andrade BB; Gonçalves MS
Sci Rep; 2019 Oct; 9(1):14829. PubMed ID: 31616024
[TBL] [Abstract][Full Text] [Related]
35. Inflammation induced by Bothrops asper venom: release of proinflammatory cytokines and eicosanoids, and role of adhesion molecules in leukocyte infiltration.
Zamuner SR; Zuliani JP; Fernandes CM; Gutiérrez JM; de Fátima Pereira Teixeira C
Toxicon; 2005 Dec; 46(7):806-13. PubMed ID: 16198389
[TBL] [Abstract][Full Text] [Related]
36. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
37. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
38. Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood.
McFaul SJ; Bowman PD; Villa VM
J Lab Clin Med; 2000 Mar; 135(3):263-9. PubMed ID: 10711865
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
40. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
